Followers | 46 |
Posts | 4547 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
Monday, March 30, 2020 4:59:01 PM
We caution that this is still early stage research and development and is not making any express or implied claims that it has the ability to eliminate the SARS-CoV-2 virus at this time. We further caution that we have not undertaken any clinical trials.
VICTORIA, March 30, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) announces that its collaborator, EVQLV, has submitted their first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against the new coronavirus, SARS-CoV-2. These DNA sequences were generated using computational antibody design, a method which combines mathematics, statistics, and computer science to identify high-affinity antibodies. The submitted antibody sequences were pre-screened by EVQLV’s artificial intelligence-driven algorithms, which work to maximize the resulting antibodies’ therapeutic potential while minimizing safety and manufacturing risks.
IPA believes treatments for the new coronavirus are ideally generated using data from the newly emerged strain, in part as the spike protein from the 2019 virus has been shown to have a unique sequence that sets it apart from the 2002 SARS-CoV and SARS-related CoVs1.
“As new insights into SARS-CoV-2 are captured by researchers around the world, we are applying these insights in an attempt to generate an efficacious and sustainable therapy. The submission of the first panel of antibody sequences by EVQLV is an important milestone,” stated Dr. Jennifer Bath, CEO of IPA.
The next step in this process for IPA is to review the antibody candidates from EVQLV’s artificial intelligence. IPA will select approximately 1,200 ideal candidates that were characterized and screened by EVQLV’s artificial intelligence and validate the antibody candidates in vitro (i.e. at IPA’s lab facilities) for the purpose of producing and testing these antibodies. IPA has sufficient financial resources to carry out this testing.
While computational analyses are routine practice in antibody optimization, it is uncommon to run millions of computational antibody designs and breadth of screening calculations performed by EVQLV’s artificial intelligence. The use of EVQLV’s technology, in conjunction with IPA’s research insights and parameters, generated this first panel of optimized antibody sequences against SARS-CoV-2 in less than one week. Given the early stage nature of discovered antibody sequences in the development chain, IPA and EVQLV will continue to work on additional panels of computationally generated sequence candidates against SARS-CoV-2.
“EVQLV’s approach simulates antibody discovery and characterization that occurs in the laboratory and generates candidate sequences which are screened using algorithms seeking desirable attributes,” said Dr. Bath. “By computationally generating and screening millions of antibody sequences, the algorithms provide our laboratory teams prospective panels of anti-SARS-CoV-2 antibody sequences for further validation.”
1Walls et al., 2020, Cell 180, 1–12
About EVQLV
EVQLV develops artificial intelligence, engineered with life science data and biological knowledge, that accelerates the speed at which biologic therapies reach patients. Comprised of experts in machine learning, molecular biology, computational biology, pharmacology, software engineering, antibody design, cloud computing, and preclinical/clinical development, EVQLV is on a mission to transform how healing reaches those in need. For further information, visit www.evqlv.com or contact Daniel Gigante at dgigante@evqlv.com.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com.
For further information: For investor relations please contact: Frederick Chabot, Phone: 1-438-863-7071, Email: frederick@contactfinancial.com, Contact Financial Corp., 1450 – 701 West Georgia St., Vancouver, BC V7Y 1G5
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30th, 2019, which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies
https://www.immunoprecise.com/immunoprecises-artificial-intelligence-partner-evqlv-submits-first-panel-of-optimized-antibody-sequences-to-coronavirus-for-polytope-mab-therapy-program/
Recent IPA News
- ImmunoPrecise Antibodies (IPA) publie ses résultats financiers et les faits saillants de ses activités du premier trimestre de l’exercice 2025 • Business Wire • 09/17/2024 02:13:00 AM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 09/16/2024 08:01:33 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 01:04:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 01:03:19 PM
- ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 • Business Wire • 09/16/2024 01:00:00 PM
- U.S. Markets Await Fed Decision and Empire State Report Amid Global Economic Shifts; Oil Prices Rise Slightly • IH Market News • 09/16/2024 10:04:55 AM
- IPA publiera le 16 septembre 2024 ses résultats financiers et les récents faits saillants de ses activités du premier trimestre de l’exercice 2024 • Business Wire • 09/09/2024 09:44:00 PM
- IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 • Business Wire • 09/09/2024 01:11:00 PM
- L'IPA participera à la 26e conférence annuelle mondiale de l'investissement organisée par H.C. Wainwright à New York • Business Wire • 08/26/2024 04:12:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/26/2024 01:41:08 PM
- ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York • Business Wire • 08/26/2024 01:00:00 PM
- ImmunoPrecise Antibodies reçoit un avis de la part du Nasdaq concernant les exigences minimales en matière d'offre • Business Wire • 08/24/2024 07:35:00 AM
- ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements • Business Wire • 08/24/2024 12:00:00 AM
- ImmunoPrecise Antibodies conçoit des anticorps in silico pour des protéines tumorales élusives en utilisant sa technologie LENSai brevetée • Business Wire • 08/19/2024 06:04:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/19/2024 01:21:46 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/19/2024 04:15:03 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/06/2024 09:16:28 PM
- ImmunoPrecise Antibodies (IPA) publie ses résultats financiers et ses mises à jour commerciales pour le quatrième trimestre et l'exercice 2024 • Business Wire • 07/30/2024 01:05:00 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/29/2024 12:38:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2024 12:35:02 PM
- ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 • Business Wire • 07/29/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/24/2024 01:55:46 AM
- ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024 • Business Wire • 07/23/2024 11:30:00 PM
- ImmunoPrecise annonce un accord de financement avec Yorkville Advisors Global, LP d'un montant en capital global de 3,0 millions USD de débentures convertibles • Business Wire • 07/17/2024 12:22:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM